500 Boylston Street, Boston, MA 02116 617-419-4700
Return to Results
We are one of approximately 40 clinics in the United States conducting a Phase 2 study of a novel investigational drug being developed to treat anemia in patients with renal disease who are not yet on dialysis. As you know, patients with chronic kidney disease are usually treated with an injectable erythropoietin, with or without parenteral iron. The drug we are studying (FG-4592) is an oral drug that stimulates endogenous production of erythropoietin. It also has the potential to facilitate iron absorption and metabolism. The drug works by inhibiting the degradation of the hypoxia inducible factor (HIF), a transcription factor involved in coordinating endogenous response to hypoxic conditions by increasing expression of the erythropoietin gene and other means. The Sponsor of the study is FibroGen, Inc (www.fibrogen.com), located in San Francisco.
We are looking for patients with Stage 3 and 4 chronic kidney disease - GFR 15 – 60 cc/min or serum creatinine in the ~1.5 – 3.0 g/dL range with hemoglobin levels under 11 g/dL who might be interested in participating in a research study. The investigational treatment (FG-4592 or placebo) is given for 4 weeks.
Sponsor: Fibrogen, Inc
Phase: Phase 2
Trial ID: FGCL-SM4592-017
Not Accepting Healthy Volunteers